Vera Therapeutics
VERA
173 hedge funds and large institutions have $2.37B invested in Vera Therapeutics in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 70 increasing their positions, 51 reducing their positions, and 24 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 51
23% more capital invested
Capital invested by funds: $1.92B → $2.37B (+$448M)
22% more call options, than puts
Call options by funds: $10.6M | Put options by funds: $8.7M
1% more funds holding
Funds holding: 171 → 173 (+2)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
0.74% more ownership
Funds ownership: 96.87% → 97.61% (+0.74%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$41.6M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$37.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.1M |
| 4 |
Millennium Management
New York
|
+$9.98M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$33.1M |
| 2 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$27.5M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$24.4M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$17.1M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$14M |
VERA Hedge Fund Activity: Q3 2024 in Review
173 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q3 2024, worth a combined $2.37B — up 23% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new VERA positions and 24 closed out — a net gain of 2 holders — while 70 added to existing stakes and 51 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $41.6M. The largest seller was Artal Group, exiting entirely with an estimated $33.1M sold.
- 173 institutional investors held Vera Therapeutics (VERA) as of Q3 2024, up from 171 in Q2 2024.
- Funds reported $2.37B of Vera Therapeutics stock for Q3 2024, up 23% quarter-over-quarter.
- 26 funds opened new Vera Therapeutics positions in Q3 2024 and 24 closed out, a net change of +2 holders.
- The largest Vera Therapeutics buyer in Q3 2024 was Paradigm Biocapital Advisors, an estimated $41.6M added.
- The largest Vera Therapeutics seller in Q3 2024 was Artal Group, an estimated $33.1M sold.
Based on aggregated 13F filings for Q3 2024.